CA
NZ
UK
AU
IND
US
● New reporting structure groups specialtyAssetstogether
● Prestige portfolio gains long-term visibility
● Full-year profit range cut sharply onCommodityandInflationpressure
● Net income fell on lower other income and a tax provision
● Additional trust taxes andAcquisitiontiming cut the outlook
● Plans to separate retail pharmacy into an independent listed company
● Net income and adjusted EPS slipped onMarketingand provision costs
● Fourth-quarterRevenueguidance came in below consensus
● Fourth-quarter guidance pointed to roughly flat sales
● Full-year revenue range raised and narrowed
Please wait processing your request...